CSL Limited (ASX:CSL) says its handling of a glitch that cut the supply of Benzylpenicillin was “clumsy”.
Chief Brian McNamee told media the biopharmaceutical company suffered from being the last supplier of the crucial antibiotic.
His admittance comes a month after CSL rationed the use of the drug because of a delivery delay from its Austrian supplier. He told the Australian it wasn’t as if the company was given a natural monopoly of the business, but "communications were clumsy".
Earlier this month CSL placed $US750 million of debt into the US private placement market, one of the largest issues made by an Australian company.
CSL was also under fire last month after a series of manufacturing flaws in its US laboratories was revealed.
CSL Limited (ASX:CSL) reported a net profit of $940.6 million for the six months to June this year.
